ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Johnson and Johnson

Johnson and Johnson (JNJ)

158.19
0.23
(0.15%)
Closed March 28 04:00PM
158.26
0.07
(0.04%)
After Hours: 07:59PM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
158.26
Bid
-
Ask
-
Volume
6,293,906
158.11 Day's Range 159.14
144.95 52 Week Range 175.97
Market Cap
Previous Close
157.96
Open
158.11
Last Trade
1
@
158.4
Last Trade Time
Financial Volume
$ 997,577,052
VWAP
158.4989
Average Volume (3m)
7,153,733
Shares Outstanding
2,408,767,228
Dividend Yield
3.01%
PE Ratio
10.84
Earnings Per Share (EPS)
14.59
Revenue
85.16B
Net Profit
35.15B

About Johnson and Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; ba... Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. This segment also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
New Brunswick, New Jersey, USA
Founded
1970
Johnson and Johnson is listed in the Pharmaceutical Preparations sector of the New York Stock Exchange with ticker JNJ. The last closing price for Johnson and Johnson was $157.96. Over the last year, Johnson and Johnson shares have traded in a share price range of $ 144.95 to $ 175.97.

Johnson and Johnson currently has 2,408,767,228 shares outstanding. The market capitalization of Johnson and Johnson is $381.04 billion. Johnson and Johnson has a price to earnings ratio (PE ratio) of 10.84.

JNJ Latest News

Walgreens Slashes Annual Profit Forecast; MillerKnoll Nosedives 17% on Bleak 4Q Outlook, and Latest News

JPMorgan Chase (NYSE:JPM) – JPMorgan Chase is looking to expand its wealth management and attract more investors by introducing the Wealth Plan tool to its 54 million Chase retail clients...

GameStop Shares Tumble 20% in Pre-Market Trading Amid Revenue Decline, Direct Digital Plummets 42%, and More News

GameStop (NYSE:GME) – GameStop reported $1.79 billion in revenue for the fourth quarter, which is less than the $2.23 billion earned in the same quarter of the previous year. However, the...

Artelo Biosciences Selected as a Finalist in Johnson & Johnson’s Innovation Challenge

SOLANA BEACH, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to...

Johnson & Johnson to Host Investor Conference Call on First-Quarter Results

Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, April 16th to review first-quarter results. Joaquin Duato, Chairman and Chief...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Johnson & Johnson Completes Acquisition of Ambrx

Acquisition strengthens Johnson & Johnson’s commitment to innovation in prostate cancer and deepens pipeline of next-generation antibody drug conjugates and targeted oncologic therapeutics...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

RYBREVANT® (amivantamab-vmjw) in Combination With Chemotherapy Is the First FDA Approved Therapy for First-line Treatment of Patients With Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

RYBREVANT® (amivantamab-vmjw) in Combination With Chemotherapy Is the First FDA Approved Therapy for First-line Treatment of Patients With Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
12.671.71604858924155.59159.14154.767604033156.01400939CS
4-3.74-2.30864197531162163.11154.767310044158.55196424CS
12-3.33-2.06077108732161.59163.58154.767153733158.9243658CS
260.760.48253968254157.5163.58144.957034728156.17169811CS
525.683.72263730502152.58175.97144.9510957545163.31664026CS
156-5.88-3.58230778604164.14186.69144.958456705166.29646941CS
26019.1713.7824430225139.09186.69109.168134455157.42887537CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AVTXAvalo Therapeutics Inc
$ 22.08
(364.84%)
31.9M
NXLNexalin Technologies Inc
$ 1.50
(92.31%)
11.67M
CEROCERo Therapeutics Holdings Inc
$ 3.112
(90.92%)
24.08M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
KYCHKeyarch Acquisition Corporation
$ 12.30
(75.58%)
196.62k
BOLDBoundless Bio Inc
 14.25
(-76.24%)
767.63k
PMECPrimech Holdings Ltd
$ 1.2999
(-66.50%)
8.28M
TNXPTonix Pharmaceuticals Holding Corporation
$ 0.1816
(-44.45%)
21.92M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
NBSTWNewbury Street Acquisition Corporation
$ 0.042279
(-38.28%)
1.75k
NKLANikola Corporation
$ 1.035
(13.85%)
163.84M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
MARAMarathon Digital Holdings Inc
$ 22.56
(2.22%)
86.14M
AKANAkanda Corporation
$ 0.1166
(-29.29%)
80.34M

JNJ Discussion

View Posts
BottomBounce BottomBounce 3 months ago
$JNJ has Total Debt (mrq) $29.92B
👍️0
IHuser IHuser 5 months ago
imo..... i have toppled bf starting w the evil worthless king flying red bull ace....those paying attention have watched in dismay...next!


JNJ PFE

IHuser
👍️0
IHuser IHuser 6 months ago
imo... this ticker is a toxic POS...FOLOW MY GROUP at PFE....


IHuser
👍️0
IHuser IHuser 6 months ago
imo...my global following will crash this stock.....and me....JNJ
👍️0
IHuser IHuser 7 months ago
imo.... if you are bullish on this ticker i will ruin you and your whole life....f with me JNJ


IHuser
👍️0
DewDiligence DewDiligence 7 months ago
JNJ’s KVUE spin-off now has its own iHub board:

https://investorshub.advfn.com/Kenvue-Inc-KVUE-42070
👍️0
1jas 1jas 7 months ago
anyone here, read about enzolytics pharm announcing the now have a cure for hiv/aids called clone 3 yesterday.
👍️0
Enterprising Investor Enterprising Investor 7 months ago
Johnson & Johnson Announces Preliminary Results of Kenvue Inc. Exchange Offer (8/21/23)

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced that, based on preliminary results, its previously announced offer to its shareholders to exchange their shares of Johnson & Johnson common stock for shares of Kenvue Inc. (NYSE: KVUE) (“Kenvue”) common stock owned by Johnson & Johnson was oversubscribed. The exchange offer expired at 12:00 midnight, New York City time, at the end of the day on August 18, 2023. Under the terms of the exchange offer, 8.0324 shares of Kenvue common stock will be exchanged for each share of Johnson & Johnson common stock accepted in the exchange offer.

According to the exchange agent, Computershare Trust Company, N.A., 802,707,331 shares of Johnson & Johnson common stock were validly tendered and not validly withdrawn, including 250,407,279 shares that were tendered by notice of guaranteed delivery. Johnson & Johnson intends to accept 190,955,436 of the tendered shares in exchange for the 1,533,830,450 shares of Kenvue common stock owned by Johnson & Johnson. Because the exchange offer was oversubscribed, Johnson & Johnson is accepting only a portion of the shares of its common stock that were validly tendered and not validly withdrawn, on a pro rata basis in proportion to the number of shares tendered. Shareholders who owned fewer than 100 shares of Johnson & Johnson common stock, or an "odd-lot," who have validly tendered all of their shares, will not be subject to proration, in accordance with the terms of the exchange offer.

Based on the total number of shares of Johnson & Johnson common stock reported to be tendered prior to the expiration of the exchange offer, it is estimated that approximately 23.8% of the tendered shares of Johnson & Johnson common stock will be exchanged, assuming all shares tendered by guaranteed delivery procedures are delivered under the terms of the exchange offer. This preliminary proration factor is subject to change based on the number of tendered shares that satisfy the guaranteed delivery procedures, as well as the number of "odd-lot" shares that were validly tendered and are not subject to proration. Johnson & Johnson expects to announce the final proration factor on August 23, 2023, promptly following the expiration of the guaranteed delivery period. Shares of Johnson & Johnson common stock tendered but not accepted for exchange will be returned to the tendering shareholders in book-entry form promptly after the final proration factor is announced. Following the completion of the exchange offer, Johnson & Johnson will retain approximately 9.5% of the outstanding shares of Kenvue common stock.

Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC are the dealer managers for the exchange offer.

About Johnson & Johnson

At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 135 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest, most diversified healthcare products company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.

https://www.businesswire.com/news/home/20230821033927/en/Johnson-Johnson-Announces-Preliminary-Results-of-Kenvue-Inc.-Exchange-Offer
👍️0
Enterprising Investor Enterprising Investor 7 months ago
The Final Exchange Ratio is 8.0324 shares of KVUE per JNJ share (unless extended).

https://www.sec.gov/Archives/edgar/data/200406/000162828023029851/vwapday19.htm
👍️0
IHuser IHuser 7 months ago
imo... this ticker is culpable as any poisoning people...JNJ










IHuser
👍️0
TRUSTUNITS1000000 TRUSTUNITS1000000 8 months ago
Type in a symbol by mistake and came up with this stock
👍️0
TRUSTUNITS1000000 TRUSTUNITS1000000 8 months ago
Type in a symbol by mistake and came up with this stock
👍️0
TRUSTUNITS1000000 TRUSTUNITS1000000 8 months ago
Nice long run
👍️0
fung_derf fung_derf 8 months ago
And.....?
👍️0
DewDiligence DewDiligence 8 months ago
Bankruptcy judge tosses JNJ’s proposed talc settlement:

https://www.wsj.com/articles/johnson-johnsons-second-talc-bankruptcy-case-thrown-out-74a63a13 A New Jersey bankruptcy judge threw out the second chapter 11 case that Johnson & Johnson filed to resolve its mass talc liabilities, again shutting down the healthcare-product company’s plan to achieve an $8.9 billion settlement [see #msg-171617699].

Judge Michael Kaplan of the U.S. Bankruptcy Court in Trenton, N.J., said that J&J affiliate LTL Management LLC, created to carry the company’s talc-related liabilities into bankruptcy, wasn’t in sufficient financial distress to warrant granting it the legal protections of chapter 11.
👍️0
DewDiligence DewDiligence 8 months ago
JNJ launches tax-free exchange offer for KVUE:

https://www.businesswire.com/news/home/20230723805654/en
👍️0
BottomBounce BottomBounce 9 months ago
J&J Vaccine and Guillain-Barré Syndrome: Information on the FDA Warning
https://www.yalemedicine.org/news/covid-vaccine-guillain-barre-syndrome $JNJ
👍️0
BottomBounce BottomBounce 9 months ago
Johnson & Johnson $JNJ Total Debt (mrq) $52.91B
👍️0
Agoura Guy Agoura Guy 10 months ago
***US FDA Revokes Emergency Use Authorization of J&J COVID-19 Vaccine***

***serious risk of blood clots***

TOO MANY DEAD PEOPLE.... JNJ KILLED TO MANY PATIENTS WITH THIS EXPERIMENTAL VACCINE POISON THAT HAD NO LONG TERM SAFETY TESTING!!!!!!

JNJ IS LIABLE FOR KILLING ALL THOSE INNOCENT PEOPLE!!!!!!

THESE CRIMINALS WILL BE SUED INTO OBLIVION!!!!!!!

SHORT THIS RANCID STOCK!!!!!!!!!


👍️ 1
DewDiligence DewDiligence 10 months ago
BMY/JNJ—Milvexian—>FDA Fast Track designation for_all_phase-3_indications:

https://finance.yahoo.com/news/milvexian-granted-u-fda-fast-105900364.html

The three Milvexian indications BMY/JNJ are pursuing in phase-3 are: secondary stroke prevention; ACS; and primary stroke prevention in patients with AF—see #msg-171338375.

FDA Fast Track status doesn’t mean much, but it makes a Priority Review of the NDAs somewhat more likely (if one or more of these phase-3 trials pan out).

Please see #msg-169818942 for additional background info.

p.s. This PR was issued yesterday.
👍️0
DewDiligence DewDiligence 10 months ago
JNJ’s talc settlement encounters a hitch:

https://endpts.com/talc-claimants-look-to-sue-jj-over-alleged-fraud-in-bankruptcy-case/
👍️0
DewDiligence DewDiligence 11 months ago
KVUE +22% on_first_day_of_trading, valuing_the_company_at ~$50B.
👍️0
DewDiligence DewDiligence 11 months ago
JNJ consumer spinoff, Kenvue IPOs @$22.00—starts_trading_today_as KVUE:

https://finance.yahoo.com/news/kenvue-begin-trading-york-stock-132500217.html

At the IPO price, KVUE’s market cap is ~$41B. Following the IPO, JNJ still owns about 90% of KVUE and plans to distribute the remainder to JNJ shareholders at some point.

Caution: KVUE bears 100% of JNJ’s talc liability outside of the US and Canada.
👍️0
Agoura Guy Agoura Guy 12 months ago
Holding Big Pharma ACCOUNTABLE: J & J To Pay Victims $8.9 Billion For Cancer Causing Baby Powder!!!!!

WHAT KIND OF MONSTERS RUN J & J?????

SMEARING CANCER ON BABIES???????

SHORT THIS CRAP TO OBLIVION!!!!!!!

👍️ 1
DewDiligence DewDiligence 12 months ago
Addendum—JNJ’s ex-North America talc liabilities are being transferred to the Kenvue spinoff, according to Kenvue’s SEC filings.
👍️0
DewDiligence DewDiligence 12 months ago
JNJ asserts_it_has_settled_North_America talc claims_for_an NPV_of_$8.9B_spread_over_25_years:

https://www.sec.gov/ix?doc=/Archives/edgar/data/0000200406/000020040623000037/jnj-20230404.htm On April 4, 2023, the Company announced that its wholly owned subsidiary LTL Management LLC (LTL) has re-filed for voluntary Chapter 11 bankruptcy protection to obtain approval of a reorganization plan that will efficiently resolve all current and future claims arising from cosmetic talc litigation against the Company and its affiliates in North America. The Company has agreed to contribute up to the present value of $8.9 billion over 25 years (nominal value approximately $12 billion) to resolve the North America talc claims… JNJ’s press release (https://www.sec.gov/Archives/edgar/data/200406/000020040623000037/a44238-kexhibit991.htm ) says: LTL also has secured commitments from over 60,000 current claimants to support a global resolution on these terms. Notably, the PR doesn’t say how many other ex-North America claimants there are (or will be) and what is meant by the phrase, “these terms.”
👍️0
DewDiligence DewDiligence 12 months ago
JNJ has earmarked $61.5B for talc liability, according to court documents:

https://www.fiercepharma.com/pharma/after-johnson-johnson-loses-again-bankruptcy-case-its-game-talc-lawsuits
👍️0
IHuser IHuser 1 year ago
imo...Mr. Putin and the white hat US are dropping these criminals...thank-you..from USA___JNJ
👍️0
BottomBounce BottomBounce 1 year ago
Court Rejects J&J Bankruptcy Petition To End Talc Cancer Lawsuits https://www.rttnews.com/3340418/court-rejects-j-j-bankruptcy-petition-to-end-talc-cancer-lawsuits.aspx $JNJ
👍️0
Sesh Sesh 1 year ago
Whoops better start digging in the cushions for some change J&J!
👍️0
BottomBounce BottomBounce 1 year ago
$JNJ Book Value only $28.51
👍️0
BottomBounce BottomBounce 1 year ago
$JNJ has $32.03B DEBT
👍️0
IHuser IHuser 1 year ago
imo...no posts....yal want me to post godsmack....ok.......ready____JNJ
👍️0
IHuser IHuser 1 year ago
imo...
👍️0
IHuser IHuser 1 year ago
imo...
👍️0
IHuser IHuser 1 year ago
imo....thank you Mr. Putin for replying to my communication...we American citizens see through these assholes bs....ty. This is our channel now where you can hear directly from the American market and the American people without interference.... subject to ihub rules....imo JNJ

Huser
👍️0
IHuser IHuser 2 years ago
imo....all world leaders be warned I now own ihub sentiment with the people and you will have a very hard time getting past me to make war......because that is not what humantity wants........so......try me. JNJ
👍️0
IHuser IHuser 2 years ago
imo...DY i se your sentiments in the green room......we are taking this over period no miscellaneous mass poisoning allowed....i hear you DY......JNJ.

Huser
👍️0
IHuser IHuser 2 years ago
imo...WW3 is called off.......subliminally.....the trumps cued me to this post....humanity does not naturally fight humanity......we don't......so quit....the bs....JNJ......everybody has money....and thats a good thing.....JNJ
👍️0
IHuser IHuser 2 years ago
imo...i can talk directly to putin on this channel....people don't have the problem...speculators are the problem......and blood doesnt spend very well....JNJ...hee sees this post and agrees with me....JNJ.
👍️0
IHuser IHuser 2 years ago
imo...my johnson is smaller than this company...JNJ
👍️0
DewDiligence DewDiligence 2 years ago
BMY/JNJ—Milvexian phase-2 data in treatment of acute ischemic stroke…

PR:
https://finance.yahoo.com/news/breaking-results-phase-2-axiomatic-073600645.html

CC slides:
https://s21.q4cdn.com/104148044/files/doc_presentations/2022/Bristol-Myers-Squibb-ESC-IR-2022-Event-Presentation.pdf

Milvexian is an oral inhibitor of Factor XIa being co-developed by BMY and JNJ (#msg-140083631). For BMY specifically, Milvexian is the company’s hope for replacing Eliquis revenue when Eliquis goes off-patent in 2028.

In the trial reported today, Milvexian + Plavix/aspirin was compared to Plavix/aspirin alone at five different Milvexian doses. Despite the lackluster results, which include a flat dose response, BMY/JNJ have committed to a phase-3 program for Milvexian in three indications: secondary stroke prevention; ACS; and primary stroke prevention in patients with AF. The phase-3 trials are slated to start by year-end 2022 (see slide #13). Curiously, the three phase-3 indications do not include either of the indications tested in phase-2, which are treatment of acute ischemic stroke (see above) and VTE prevention (#msg-166773814).

The main competition for Milvexian is Bayer’s Asundexian, another oral FXIa inhibitor that just started phase-3 trials in AF/stroke prevention and treatment of acute ischemic stroke (https://www.businesswire.com/news/home/20220828005030/en ).

BMY has pegged Milvexian is a $5B+ opportunity (not risk adjusted—see slide #20), but this seems optimistic in light of the dataset released today.
👍️0
Tamtam Tamtam 2 years ago
Johnson and Johnson (JNJ)
179.53 ? -1.56 (-0.86%)
Volume: 16,367,427
👍️0
Chrism0000 Chrism0000 2 years ago
PLEASE!! BUY UEEC, but it has to be for at least "8B :)) so I can retire. Lol
👍️0
Tamtam Tamtam 2 years ago
Johnson and Johnson (JNJ)
180.09 ? -0.57 (-0.32%)
Volume: 6,188,193
👍️0
Tamtam Tamtam 2 years ago
Johnson and Johnson (JNJ)
174.56 ? -2.24 (-1.27%)
Volume: 13,809,537
👍️0
wedman wedman 2 years ago
You are spot on!
👍️0
ofspring ofspring 2 years ago
NEW ?? Johnson & Johnson has suspended production at a key plant manufacturing the Covid-19 vaccine

More: https://cutt.ly/SOVMeXD
👍️0
Tamtam Tamtam 2 years ago
Possibly
👍️0
Chrism0000 Chrism0000 2 years ago
Will J&J buy them down the road? HENDERSON, Nev.--(BUSINESS WIRE)--United Health Products, Inc. (OTC: UEEC) (“UHP” or the “Company”), developer, manufacturer and marketer of HemoStyp, a patented Oxidized Regenerated Cellulose (ORC), today announced that the Journal of Wound Care, headquartered in London, England, has informed the Company that UHP’s submitted article, Efficacy and Safety of HemoStyp as an Adjunct for Management of Secondary Hemostasis in the Operative Setting, has been accepted for publication in the November 2020 edition. This article, which was peer reviewed, was authored by Raymond Schaerf, MD, Sasan Najibi, MD, John Conrad, MD, and Gerard Abate, MD. This journal submission highlights the results of the study showing HemoStyp’s superiority to Surgicel®, an Ethicon Inc. product, a division of Johnson & Johnson.

Dr. Gerard Abate, Chief Medical Officer, United Health Products, stated: “This is the first head-to-head trial of two ORCs. The data demonstrates that HemoStyp consistently achieved hemostasis faster than Surgicel in all surgical classes studied in less than two minutes, whereas Surgicel could not and failed to control bleeding in six (6) patients where the control timed out at 10 minutes. Based on the overall data, upon anticipated PMA approval for class III FDA surgical use, surgeons will have a superior product to utilize for low grade surgical bleeds.”
👍️0

Your Recent History

Delayed Upgrade Clock